Numinus Wellness (TSE:NUMI) has released an update.
Numinus Wellness Inc. responds to the FDA’s request for an additional study on MDMA-assisted therapy for PTSD, emphasizing their commitment to advancing psychedelic therapy despite the setback. The company asserts its operational profitability is not reliant on new therapy commercialization, highlighting its substantial experience in mental health treatments and ongoing research in psychedelic medicines.
For further insights into TSE:NUMI stock, check out TipRanks’ Stock Analysis page.
